ethylketocyclazocine has been researched along with Carcinoma, Anaplastic in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Alexaki, VI; Castanas, E; Hatzoglou, A; Kampa, M; Papakonstanti, EA; Stournaras, C | 1 |
1 other study(ies) available for ethylketocyclazocine and Carcinoma, Anaplastic
Article | Year |
---|---|
The opioid agonist ethylketocyclazocine reverts the rapid, non-genomic effects of membrane testosterone receptors in the human prostate LNCaP cell line.
Topics: Actin Cytoskeleton; Analgesics, Opioid; Binding Sites; Binding, Competitive; Carcinoma; Cell Division; Cell Membrane; Ethylketocyclazocine; Focal Adhesion Kinase 1; Focal Adhesion Protein-Tyrosine Kinases; Humans; Male; Opioid Peptides; Prostate-Specific Antigen; Prostatic Neoplasms; Protein-Tyrosine Kinases; Reaction Time; Receptors, Androgen; Serum Albumin, Bovine; Signal Transduction; Testosterone; Tumor Cells, Cultured | 2004 |